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Abstract The potent serotonin re- 
ceptor (5-HT3) antagonists are new 
highly selective agents for the pre- 
vention and control of chemothera- 
py-induced nausea and vomiting 
that have been shown to be com- 
parable to or more effective than 
traditional metoclopramide r gi- 
mens. This study was designed to 
compare the antiemetic efficacy of 
dolasetron and metoclopramide in 
chemotherapy-naive and non-naive 
cancer patients receiving high-dose 
cisplatin-containing chemotherapy. 
This multicentre, double-blind, ran- 
domized trial compared the effica- 
cy and safety of single i.v. doses of 
dolasetron mesilate salt (1.2 or 
1.8 mg/kg) and metoclopramide 
(7 mg/kg) in 226 patients for the 
prevention of acute emesis and 
nausea associated with the admin- 
istration of high-dose ( _> 80 mg/m 2) 
cisplatin. Efficacy and safety were 
evaluated for 24 h. Complete re- 
sponses were achieved by 57%, 
48%, and 35% of patients given 
dolasetron mesilate 1.8 mg/kg 
(P = 0.0009 vs metoclopramide), 
dolasetron mesilate 1.2 mg/kg 
(P = 0.0058 vs metoclopramide), 
and metoclopramide, respectively. 
Overall, dolasetron was significant- 
ly more effective than metoclo- 
pramide for time to first emetic 
episode, nausea, patient satisfac- 
tion, and investigator global assess- 
ment of efficacy. Males, chemo- 
therapy-naive patients, and alco- 
holics had higher response rates. 
Dolasetron was weil tolerated, with 
mild-to-moderate h adache most 
commonly reported. Twelve per- 
cent of patients receiving metoclo- 
pramide reported extrapyramidal 
symptoms compared with 0% of 
patients receiving dolasetron. In 
conclusion, dolasetron mesilate was 
effective for the prevention of 
CINV with high-dose cisplatin. Sin- 
gle i.v. doses of dolasetron mesilate 
were more effective than 7 mg/kg 
metoclopramide in preventing nau- 
sea and vomiting induced by highly 
emetogenic cisplatin-containing 
chemotherapy. In addition, 1.8 mg/ 
kg dolasetron mesilate consistently 
produced the highest response 
rates and appears to be the most 
effective dose for further clinical 
development. 
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Introduction 
Chemotherapy-induced nausea and vomiting area  pri- 
mary concern in the treatment of patients with cancer, 
since uncontrolled nausea nd emesis can result in seri- 
ous medical complications, poor quality of life, and a 
potentially life-threatening failure to continue treat- 
ment [9, 28]. 
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High-dose metoclopramide (7-10mg/kg per day) 
has been shown to be effective as a single agent in the 
treatment of cisplatin-induced emesis [16, 17] and has 
been shown to be effective when administered as a con- 
tinuous infusion [40]. Metoclopramide-based combina- 
tion antiemetic therapies have further improved the 
emesis associated with cisplatin-containing chemother- 
apy [14, 25, 36]. However, none of these combination 
regimens is fully effective. Furthermore, owing to its 
antidopaminergic properties, metoclopramide is fre- 
quently associated with unwanted and disabling extra- 
pyramidal reactions, and anxiety and depression [2, 4, 
16, 39]. 
The potent serotonin receptor (5-HT3) antagonists 
are new, highly selective agents for the prevention and 
control of nausea and vomiting after cytotoxic chemo- 
therapy [15, 22]. These compounds have been shown to 
be comparable to or more effective than traditional me- 
toclopramide regimens [1, 18, 30, 37], and their use is 
not accompanied by distressing extrapyramidal side ef- 
fects [19, 22]. Some of these new agents also offer the 
convenience of once-daily dosing and can be then ad- 
ministered in a single i.v. dose [15]. 
Dolasetron mesilate (Anzemet, Hoechst Marion 
Roussel) is a new pseudopelletierine-derivative that is 
highly selective for 5-HT» receptors and is a potent 5- 
HT3 receptor antagonist [6, 13, 32]. Dolasetron is rap- 
idly and almost completely metabolized to a more po- 
tent and more selective metabolite (MDL 74,156) that 
has a longer half-life than the parent compound [5, 7]. 
Development of dolasetron dosing was based on the 
mesilate salt. Therefore, all references to doses reflect 
that of the salt and can be adjusted to the equivalent 
base by multiplying by 0.74; thus, the dolasetron mesi- 
late doses of 1.8 and 2.4 mg/kg are equivalent to 0.9 and 
1.3 mg/kg, respectively. Dose-ranging studies have sug- 
gested that i.v. dolasetron has substantial antiemetic ef- 
fects and is well tolerated by patients receiving moder- 
ately or highly emetogenic chemotherapy [8, 23, 24, 27, 
31]. These studies also showed that the dose with maxi- 
mal antiemetic activity was a single i.v. dose of 1.8 mg/ 
kg, and that efficacy did not increase substantially with 
higher single i.v. doses. 
Double-blind, randomized trials in patients un- 
dergoing high-dose cisplatin-containing chemotherapy 
have confirmed ose-ranging results [3, 21, 41]. Patients 
who received a single 1.8 mg/kg dose of dolasetron me- 
silate achieved significantly higher rates of complete re- 
sponse (no emetic episodes and no escape antiemetic 
medication), complete or major response (_< 2 emetic 
episodes and no escape antiemetic medication), and 
significantly longer times to the first emetic episode 
than those who received 0.6 mg/kg [41]. Furthermore, 
another study [21] demonstrated that a single i.v. 
1.8 mg/kg dose of dolasetron mesilate was more effica- 
cious than 0.6 mg/kg administered three times per day. 
Our study compared two different i.v. doses of dola- 
setron mesilate with metoclopramide in a three-arm, 
double-blind, randomized parallel study with three ma- 
jor objectives. The first was to determine whether sin- 
gle-dose dolasetron mesilate (1.2 mg/kg or 1.8 mg/kg) 
was as effective as or more effective than the approved 
regimen of metoclopramide (3 mg/kg i.v. loading dose 
followed by a continuous 8-h infusion of 4 mg/kg) in 
preventing emesis caused by high-dose cisplatin. The 
second was to compare the tolerability of dolasetron 
and metoclopramide, and the third was to compare pa- 
tient satisfaction with each of the three antiemetic re- 
gimens. 
Patients and methods 
Patients 
From January 1992 to February 1994, 226 male and female cancer 
patients receiving cisplatin-containing chemotherapy were en- 
rolled at 13 centres throughout Europe. At 12 of these centres, 
patients received cisplatin at a dose of _> 80 mg/m 2over 3 h; at 
orte centre, patients received 70 mg/m 2cisplatin over 4 h. Both 
chemotherapy-naive patients and those who had previously re- 
ceived cytotoxic hemotherapy were admitted into the study. The 
protocol for this study was approved by the appropriate institu- 
tional review boards and all patients gave written informed con- 
sent. 
Patients were excluded from the study if they had a history of 
significant neurologieal or psychiatric illness (except alcoholism), 
a history of congestive heart failure, arrhythmias requiring medi- 
cation, heart block greater than first degree, cardiotoxicity from 
cumulative doses of anthracyclines/anthracenediones, abnormal 
serum potassium or calcium concentrations, or evidence of liver 
disease. Patients who had received investigationaI drugs within 21 
days of the study, chemotherapy in the 72 h before cisplatin, and 
treatments hat might interfere with the study results were also 
excluded from the trial. In addition, patients were disqualified if 
they experienced severe nausea or vomiting (severity of 2-4 ac- 
cording to the Southwest Oncology Group scale) within 24 h be- 
fore chemotherapy, as were those who experienced vomiting 
from any organic aetiology. 
Study procedures 
After pretreatment screening, eligible patients were stratified by 
gender and prior chemotherapy history (naive, non-naive) and 
randomly assigned to treatment. Patients received either 1.2 mg/ 
kg or 1.8 mg/kg dolasetron mesilate as a single i.v. dose over 
15 min, beginning 30 min before cisplatin, or metoclopramide 
(3 mg/kg i.v. loading dose over 15 min, 30 min before cisplatin, 
followed by 4 mg/kg as a continuous 8-h infusion beginning at the 
same time as cisplatin). 
To maintain the blind nature of the study, each test drug was 
diluted with sterile 0.9% NaC1 so that each patient received ato- 
tal infusion of 50 ml. In addition, a double-dummy administration 
technique was used. The first administration of metoclopramide 
(3 mg/kg) or dolasetron mesilate (1.2 or 1.8 mg/kg) began 30 min 
before the cisplatin infusion and consisted of a 50 ml i.v. infusion 
over a period of 15 min. On the basis of body weight require- 
ments (_< 100 kg), it was known that not more than two ampules 
of dolasetron or placebo and not more than two ampules of me- 
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toclopramide or placebo would be used for an individual patient. 
The second administration f metoclopramide (4 mg/kg) or place- 
bo began at the same time as cisp!atin administration a d consist- 
ed of a 500 ml i.v. infusion over a period of 8 h. Additional che- 
motherapy could be given during the 24 h following the start of 
cisplatin administration. 
Evaluation of efficacy 
All evaluations for efficacy were made during a 24-h evaluation 
period measured from the initiation of cisplatin infusion (hour 0). 
The number and timing of emetic episodes during the evaluation 
period were recorded. An emetic episode was defined as one oc- 
currence of vomiting or a sequence of occurrences in very close 
succession ot relieved by a period of relaxation, any number of 
occurrences of unproductive emesis (retching) in a single 5-min 
period, or an episode of retching of less than 5 min duration com- 
bined with vomiting that was not relieved by a period of relaxa- 
tion. 
Antiemetic efficacy was evaluated according to the following 
criteria: complete response was defined as no emetic episodes and 
no use of escape antiemetic medication, and treatment failure was 
recorded for any patient who had three or more emetic episodes 
or needed escape antiemetic medication during the 24 h after the 
start of chemotherapy. A patient who was not evaluated for eme- 
sis for 24 h after the start of chemotherapy was also categorized as 
a treatment failure. In addition, the time to the first emetic epi- 
sode and the time to escape antiemetic medication were re- 
corded. 
Patients assessed the severity of nausea 45 min before, imme- 
diately before, and 24 h after the start of cisplatin infusion (hour 
0) according to a visual analogue scale (VAS) that ranged from 
"no nausea" (0 mm) to "nausea s bad as it can be" (100 mm). At 
hour 24, patients rated their most severe pisode of nausea over 
the 24-h evaluation period. Patient satisfaction was also evaluated 
according to a VAS ranging from "not at all satisfied" (0 mm) to 
"completely satisfied" (100 mm). In addition, investigators e- 
ported their global assessment of efficacy according to a rating 
scale of 0 to 3 (no, slight, good, excellent efficacy), and the pa- 
tient's most severe nausea during the 24-h evaluation period ac- 
cording to a discrete scale of 0 to 3 (no, slight, moderate, severe 
nausea). 
Evaluation of safety 
Physical examinations and clinical aboratory tests were perform- 
ed prior to treatment and at hour 24. Vital signs were assessed 
15 min before the administration f study medication and at 0.5, 
4, 8, and 24 h after the start of cisplatin. Electrocardiograms 
(ECGs), obtained within 3 days before treatment, were repeated 
at hour 24 in centres that could accommodate this test. Although 
other studies have demonstrated clinically unimportant, asympto- 
matic alterations in ECG parameters with dolasetron treatment 
[23, 41], the minimal cardiac monitoring inthis study could not be 
used to make judgements on ECG alterations from dolasetron. 
All patients were monitored for adverse vents throughout the 
24-h treatment period. 
Statistical analyses :~ 
A sample size of 100 patients per treatment group was estimated 
as described previously [34], and based on a = 0.05,/~ = 0.20, and 
an assumed complete response rate of 40% for the metoclopram- 
ide group and a 60% complete response rate for the dolasetron 
mesilate 1.8 mg/kg group. A difference of 20% in the response 
rates between treatment group was necessary for a conclusion of 
superiority. Because of slow recruitment, enrollment was termi- 
nated with 226/300 patients enrolled. Baseline patient characteris- 
tics were compared among treatment groups by the Kruskal-Wal- 
lis one-way analysis of variance for quantitative ariables and the 
Chi-square or Fisher's exact est for categorical variables. 
The primary test of efficacy was a pairwise comparison be- 
tween dolasetron mesilate 1.8 mg/kg and metoclopramide. Pair- 
wise tests of dolasetron mesilate 1.2 mg/kg versus metoclopram- 
ide and 1.2 mg/kg dolasetron mesilate versus 1.8 mg/kg dolasetron 
mesilate were also eonducted. Complete response rates were 
compared by logistic regression with confidence intervals for the 
odds ratio controlling for stratum (gender, prior chemotherapy 
status) and investigator. Logistic regression and a main effect test 
were used to test for differences in response rates across strata. 
Pairwise confidence intervals and hypothesis tests were used to 
test for differences between treatment groups. Complete plus ma- 
jor response rates were also assessed by the logistic regression 
method. 
Secondary efficacy analyses included: Cox regression analysis 
of time to first emesis or use of escape antiemetic medication; 
rank analysis of covariance for patient nausea VAS and overall 
patient satisfaction VAS; and, a Mantel-Haenszel raw mean score 
difference test for analyses of investigator global assessment of 
efficacy and rating of patients' "most severe nausea". 
Results 
Patients 
A total of 300 patients (100 per arm) were intended to 
be recruited for the study, but as the study progressed, 
antiemetic combinat ion regimens using 5-HT» antagon- 
ists became more widely used. Because the new 5-HT» 
antagonists were preferable to metoclopramide, pat ient 
enro l lment  slowed or stopped and the study was con- 
ducted with a total of 226 patients, 225 of whom were 
included in the intent-to-treat populat ion (1 patient 
dropped out as the result of a serious adverse vent fol- 
lowing the administrat ion of study medicat ion but prior 
to receiving chemotherapy);  218 were evaluable for ef- 
ficacy (6 patients received medications with antiemetic 
activity and 1 pat ient had anticipatory vomiting). 
The demographic haracteristics for patients en- 
rolled at 13 European centres are shown in Table 1. 
There were no statistically significant differences be- 
tween the three t reatment  groups with respect o gen- 
der, age, height, weight, or Karnofsky performance sta- 
tus. Overall, the pat ient populat ion consisted mainly of 
men (71%) and mean ages ranged between 54 and 56 
years in the three t reatment  groups. Head and heck, di- 
gestive, and gynaecological neoplasms were the most 
prevalent. There were also no statistically significant 
differences across t reatment  groups with respect o pri- 
or use of chemotherapeut ic  agents, cisplatin dose and 
durat ion of cisplatin infusion. The mean cisplatin dose 
for each o f  the groups was 92.2 mg/m 2 ( range:60-  
105mg/m 2) for the 1.2mg/kg dolasetron mesilate 
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Table 1 Demographic and 
baseline characteristics Characteristic 
Gender (%) 
Male 
Female 
Age(years) 
Mean _+ SD 
Weight (kg) 
Mean + SD 
Height (cm) 
Mean + SD 
Karnofsky score 
Mean + SD 
Prior chemotherapy (%) 
Male naive 
Female naive 
Male non-naive 
Female non-naive 
Site of primary neoplasm 
Breast 
Gastrointestinal 
Epidermal 
Genitourinary 
Gynaecological 
Head/neck 
Musculoskeletal 
Respiratory 
Unknown 
Dolasetron Dolasetron Metoclopramide 
mesilate mesilate 7 mg/kg 
1.2 mg/kg 1.8 mg/kg (n = 69) 
(n =84) (n =73) 
56 (67) 52 (71) 52 (75) 0.498 
28 (33) 21 (29) 17 (25) 
55 + 12 54 + 10 56 + 9 0.380 
64_+12 62_+13 62_+11 - 
168 + 8 169 -+ 9 169 -+ 9 0.769 
85 _+ 13 84 _+ 13 81 _+ 12 0.773 
30 (36%) 31 (42%) 27 (39%) 0.720 
11 (13%) 9 (12%) 10 (14%) 
26 (31%) 21 (29%) 25 (36%) 
17 (20%) 12 (16%) 7 (10%) 
3 4 2 
17 17 15 
1 0 0 
6 3 3 
14 10 8 
24 23 24 
3 3 1 
9 12 12 
7 1 4 
P value 
0.842 
group, 95.0 mg/m 2 (range: 80-120 mg/m 2) for the 
1.8 mg/kg dolasetron mesilate group and 94.4 mg/m 2 
(range: 60-120 mg/m 2) for the metoclopramide group. 
Most (209/225 or 93%) of the patients received oth- 
er anticancer agents in addition to cisplatin. Fluoroura- 
cil (56%), etoposide (21%), and cyclophosphamide 
(12%) were the most frequently administered. Statisti- 
cally significant (P=0.025) differences in the percent- 
age of patients receiving additional chemotherapy were 
noted across treatment groups; 96%, 87%, and 97% for 
metoclopramide, 1.2 mg/kg dolasetron mesilate, and 
1.8 mg/kg dolasetron mesilate, respectively. However, 
there were no significant differences across treatment 
groups with respect o the use of specific agents. 
Efficacy evaluations 
Efficacy determinations for the three antiemetic treat- 
ments are summarized in Table 2. Complete responses 
were achieved by 57% of patients in the 1.8 mg/kg do- 
lasetron mesilate group, 48% of those in the 1.2 mg/kg 
dolasetron mesilate group and, 35% of those treated 
with metoclopramide. Both doses of dolasetron were 
significantly more effective than metoctopramide in
preventing cisplatin-induced emesis (P=0.0009 for 
1.8 mg/kg dolasetron mesilate versus metoclopramide, 
P = 0.0058 for 1.2 mg/kg dolasetron mesilate versus me- 
toclopramide). In addition, there was no statistically 
significant difference between the proportion of com- 
plete responses produced by the two dolasetron mesi- 
late doses (P=0.4733). 
The median time to first emetic episode or use of 
scape antiemetic medication was »24.0, 22.5, and 5.5 h 
for patients treated with 1.8 mg/kg dolasetron mesilate, 
1.2 mg/kg dolasetron mesilate, and metoclopramide, re- 
spectively (Table 2). Both dolasetron mesilate doses 
were significantly superior to metoclopramide 
(P = 0.0003 for 1.8 mg/kg dolasetron mesilate, 
P =0.0001 for 1.2 mg/kg dolasetron mesilate). The two 
dolasetron mesilate doses were statistically similar with 
respect o time to first emetic episode. 
There was a significant (P=0.002) difference in 
complete response rates across and within strata (Table 
3). Men (56%, 89/160) had significantly (P=0.0001) 
higher complete response rates than women (25%, 16/ 
65). In addition, significantly (P=0.0448) higher rates 
of complete response were observed in chemotherapy- 
naive patients (53%, 63/118) than in those who had re- 
ceived prior chemotherapy (39%, 42/107). Subgroup 
analyses also indicated that history of alcohol abuse 
was associated with a higher overall level of response 
(P=0.0022). Patients with no history of alcohol abuse 
had an overall complete response rate of 36%, whereas 
those with a history of alcoholism had a 70% complete 
response rate. The response rates within strata were 
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Table 2 Efficacy of dolasetron and metoclopramide forprevention of cisplatin-induced mesis 
Response a Dolasetron Dolasetron Metoclopramide P value P value 
mesilate mesilate 7 mg/kg 1.8 mg/kg 1.2 mg/kg 
1.2 mg/kg 1.8 mg/kg (n = 69) vs vs 
(n = 84) (n = 72) metoclopramide metoclopramide 
Complete 48% 57% 35% 0.0009 0.0058 
Median time 22.5 > 24.0 5.5 0.0003 0.0001 
to first emetic 
episode (h) 
a Complete response =no emetic episodes and no escape antiemetic medication; treatment failure = > 3 emetic episodes and/or escape 
antiemetic medication 
Table 3 Complete response Stratum Dolasetron Dolasetron Metoclopramide 
rates by strata mesilate mesilate 7 mg/kg 
1.2 mg/kg 1.8 mg/kg (n = 69) 
(n =84) (n =72) 
Male naive (n =88) 19/30 (63) 22/31 (71) 10/27 (37) 
Male non-naive (n=72) 14/26 (54) 13/21 (62) 11/25 (44) 
Female naive (n =30) 5/11 (45) 4/9 (44) 3/10 (30) 
Female non-naive (n =35) 2/17 (12) 2/11 (18) 0/7 (0) 
All strata (n =225) 40/84 (48) 41/72 (57) 24/69 (35) 
Table 4 Control of nausea ssessed by visual analogue scale 
Assessment Dolasetron Dolasetron Metoclopramide P value P value 
mesilate mesilate 7 mg/kg 1.8 mg/kg 1.2 mg/kg 
1.2 mg/kg 1.8 mg/kg vs vs 
metoclopramide metoclopramide 
Patient assessment 37 
(% with no nausea over 24 h) 
Investigator 38 
assessment of maximum nausea 
(% with no nausea) 
51 33 0.019 0.139 
51 29 0.002 0.049 
similar to those across strata. Overall, dolasetron mesi- 
late 1.8 mg/kg was more effective than dolasetron mesi- 
late 1.2 mg/kg, which was more effective than metoclo- 
pramide. 
Patients' overall assessment of nausea and investiga- 
tors' assessment of patients' maximum severity of nau- 
sea by VAS are summarized in Table 4. The percentage 
of patients reporting "no nausea" at the 24-h VAS was 
50% for the 1.8 mg/kg dolasetron mesilate group, 37% 
for the 1.2 mg/kg dolasetron mesilate group, and 33% 
for the metoclopramide group. Dolasetron mesilate 
1.8 mg/kg was significantly (P=0.019) more effective 
than metoclopramide in controlling nausea. Investiga- 
tor assessment of patients' maximum level of nausea 
supported this finding (P=0.002, 1.8 mg/kg dolasetron 
mesilate versus metoclopramide). More than 50% of 
the patients randomized to receive metoclopramide 
were rated by the investigators as having moderate or 
severe nausea. 
Overall patient satisfaction with treatment and in- 
vestigators' global assessment of antiemetic efficacy are 
shown in Table 5. Patients and investigators favoured 
dolasetron over metoclopramide for both analyses. 
Both dolasetron mesilate doses demonstrated statisti- 
cally significant superiority (P~0.05) to metoclopramide 
in each instance. 
Safety 
There were no statistically significant differences in the 
overall incidence of adverse ffects between the dolase- 
tron mesilate 1.2 mg/kg (46%, 39/84), dolasetron mesi- 
late 1.8 mg/kg (53%, 39/73), and metoclopramide (61%, 
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Table 5 Patient satisfaction and investigator global assessment of efficacy 
Assessment Dolasetron Dolasetron Metoclopramide P value P value 
mesilate mesilate 7 mg/kg 1.8 mg/kg 1.2 mg/kg 
1.2 mg/kg 1.8 mg/kg vs vs 
metoclopramide metoclopramide 
Patient satisfaction: 59 
mean score (mm) on VAS a 
Nivestigator's global 36 
assessment of efficacy 
(% excellent) b 
73 54 0.002 0.0457 
42 20 0.006 0.049 
a Visual analogue scale measured on a 100-mm scale, with 0 indi- 
cating "not at all satisfied" and 100 indicating "completely satis- 
fied" 
b Measured on a scale of 0 =none, 1 = slight, 2 = good, and 3 = ex- 
cellent 
Table 6 Summary of adverse 
events reported by _> 3% of 
patients" 
a Values represent umber 
(%) of patients reporting an 
adverse vent 
Event Dolasetron Dolasetron Metoclopramide 
mesilate mesilate 7 mg/kg 
1.2 mg/kg 1.8 mg/kg (n = 69) 
(n =84) (n =73) 
Headache 10 (12) 13 (18) 4 (6) 
Diarrhoea 10 (12) 10 (14) 13 (19) 
Hypertension 2 (2) 8 (11) 9 (13) 
Hepatic dysfunction ó (7) 1 (1) 1 (1) 
Abdominal pain 1 (1) 2 (3) 3 (4) 
Hypotension 0 3 (4) 2 (3) 
Increased sweating 3 (4) 0 2 (3) 
Hot flushes 2 (2) 0 3 (4) 
42/69) treatment groups. Adverse events were general- 
ly mild to moderate in intensity. Overall, the most fre- 
quently reported adverse events were headache (12%, 
27/226), diarrhoea (16%, 36/226), and hypertension 
(8%, 19/226). 
As shown in Table 6, mild to moderate headache 
was more frequent in the dolasetron groups (15%, 23/ 
157 overall; 18%, 13/73 in the 1.8 mg/kg group; 12%, 
10/84 in the 1.2 mg/kg group) than in the metoclopram- 
ide group (6%, 4/69), but these differences were not 
statistically significant. Gastrointestinal events were 
more frequent in the metoclopramide group (35%, 24/ 
69) than in the dolasetron groups (22%, 34/157). Diar- 
rhoea, the most common gastrointestinal adverse vent, 
was reported in 22% (15/69) of those receiving meto- 
clopramide, compared with only 12% (10/84) of pa- 
tients receiving 1.2 mg/kg dolasetron mesilate and 15% 
(11/73) of those receiving 1.8 mg/kg dolasetron mesi- 
late. Hypertension was observed in 2% (2/84; 1 mild, 1 
severe) of patients in the 1.2 mg/kg dolasetron mesilate 
group, 11% (8/73; 7 mild, 1 moderate) of patients in the 
1.8 mg/kg dolasetron mesilate group, and 13% (9/69; 7 
mild, 2 moderate) of patients in the metoclopramide 
group. 
Eight patients in the metoclopramide group experi- 
enced adverse events that could be regarded as extra- 
pyramidal effects, including extrapyramidal disorder (1 
patient), shaking (1 patient), slurred speech (2 pa- 
tients), stift jaw (2 patients), thick tongue (1 patient), 
and tremor (1 patient). No such events were reported 
in either of the dolasetron-treated groups of patients. 
Overall, 16 patients experienced severe adverse 
events. These included 7 patients in the metoclopram- 
ide group, 6 patients in the dolasetron mesilate 1.2 mg/ 
kg group, and 3 patients in the dolasetron mesilate 
1.8 mg/kg group. Three deaths occurred in this study, 
outside the 24-h treatment period, in patients who were 
randomized to receive 1.2 mg/kg dolasetron mesilate. 
These deaths resulted from dyspnoea, septic shock, and 
acute renal failure and were attributed to progression 
of the patients' primary neoplasm or to events second- 
ary to cancer by the investigator. One patient who re- 
ceived dolasetron developed severe hypotension. This 
patient later developed other cardiac symptoms, includ- 
ing hypotension and pulmonary oedema, during other 
chemotherapy c cles. The severe hypotension was not 
considered to be related to dolasetron treatment. 
28 
Discussion 
This prospective, randomized trial demonstrated dola- 
setron to be superior to metoclopramide in the preven- 
tion of cisplatin-induced mesis. Patients who received 
single i.v. doses of 1.2 and 1.8 mg/kg dolasetron mesi- 
late had higher complete response rates, lower failure 
rates, and longer median times to first emesis during 
the study than patients who received metoclopramide. 
Complete responses were achieved by 57% of pa- 
tients in the dolasetron mesilate 1.8 mg/kg group, 48% 
of patients in the dolasetron mesilate 1.2 mg/kg group, 
and 35% of patients in the metoclopramide group. The 
complete response rates in this study were similar to 
those reported in other trials using a single i.v. dose of 
1.8 mg/kg of dolasetron mesilate for the prevention of 
cisplatin-induced mesis [3, 21, 41]. In addition, the 
complete response rates observed were also consistent 
with rates reported for other single-agent 5-HT3 antag- 
onist regimens [1, 12, 29] and for metoclopramide [14, 
20, 30] in patients undergoing highly emetogenic che- 
motherapy. In this study, 1.8 mg/kg dolasetron mesilate 
was clearly superior to metoclopramide for all antie- 
metic endpoints. 
It is well documented that patients receiving cispla- 
tin without antiemetic support experience their most 
intense mesis during the first 6 h after treatment [10]. 
The marked difference between dolasetron and meto- 
clopramide with respect o median time to first emetic 
episode - 5.5 h for metoclopramide, 22.5 h for 1.2 mg/ 
kg dolasetron mesilate and »24 h for 1.8 mg/kg dolase- 
tron mesilate - again demonstrates the superiority of 
dolasetron over metoclopramide for control of emesis 
in this group of patients. Patients also noted a marked 
preference for dolasetron over metoclopramide accord- 
ing to VAS assessments of satisfaction with overall an- 
tiemetic ontrol and control of nausea. The superiority 
of 1.8 mg/kg dolasetron mesilate over metoclopramide 
was also reflected in the investigators' global assess- 
ment of efficacy and their ratings of patients' most se- 
vere episode of nausea. 
When the present study was initiated, high-dose me- 
toclopramide was an integral part of effective antiemet- 
ic combination therapy [26], despite its capacity for in- 
duction of extrapyramidal reactions, particularly in ad- 
olescents. However, as the study progressed, a number 
of new 5-HT3 receptor antagonists received approval in 
Europe for the prevention of emesis in patients receiv- 
ing cytotoxic hemotherapy. Because these agents had 
a more acceptable adverse vent profile than metoclo- 
pramide, they were more attracfive to patients and in- 
vestigators than previous tandard therapy. As a conse- 
quence, patient enrollment into this study slowed dra- 
matically and patient recruitment was terminated early. 
Nevertheless, the total number of patients enrolled 
(226) is large enough to give the study sufficient power 
to distinguish statistically between the three treatment 
arms. 
It has been shown that the effectiveness of antiemet- 
ic agents in controlling chemotherapy-induced emesis 
and nausea varies not only according to the antiemetic 
regimen used but also according to patient characteris- 
tics. Nausea and vomiting may be more severe or hard- 
er to prevent in female patients and in those who have 
had prior chemotherapy [8, 12, 15, 18]. To control for 
these factors, patients in this study were stratified by 
gender and prior exposure to chemotherapy before 
randomization. Subgroup analyses howed that com- 
plete response rates were up to two times higher for 
male than for female patients; this difference was con- 
sistent across all treatment arms. In addition, when 
comparisons were made within each gender stratum for 
chemotherapy-naive rsus non-naive patients, re- 
sponses were more favourable in chemotherapy-naive 
patients. This difference was particularly marked 
among female patients. The highest complete response 
rate (71%) was achieved by male chemotherapy-naive 
patients who received 1.8 mg/kg dolasetron mesilate 
and the lowest (0%), by female, non-chemotherapy- 
naive patients who received metoclopramide. 
Subgroup analyses also demonstrated that prior his- 
tory of alcohol abuse was a significant predictor of re- 
sponse. Complete response rates were higher in pa- 
tients with a history of alcoholism than in those without 
(P = 0.0022), a finding that is consistent with results of 
previous tudies [11, 15, 18, 38]. No significant differ- 
ences in treatment response were found in any group 
when patients were stratified for age, Karnofsky score, 
or use of narcotic analgesics. 
Dolasetron was well tolerated in this study, with ad- 
verse events mild to moderate in intensity and similar 
to those reported for other 5-HT3 receptor antagonists 
[15, 18]. Headache was most commonly reported, also 
with similar intensity to that experienced with other 5- 
HT3 antagonists, including ondansetron and granise- 
tron [15, 18, 29, 33, 35]. Unlike metoclopramide, dola- 
setron led to no extrapyramidal reactions in either dose 
group. There were no deaths and no serious adverse 
events with dolasetron treatment. 
In summary, this double-blind, parallel-group study 
demonstrated that dolasetron is both safer and more ef- 
fective than metoclopramide in the prevention of eme- 
sis and nausea induced by high-dose cisplatin therapy. 
In addition, 1.8 mg/kg dolasetron mesilate consistently 
produced higher response rates than 1.2 mg/kg dolase- 
tron mesilate or metoclopramide forall antiemetic end- 
points and warrants further clinical development. 
Acknowledgements The authors acknowledge the editorial as- 
sistance of Marc Eisenberg, Ph.D., Gary McQuarrie, Pharm.D., 
and Neil Malone, M.S. This study was supported by a grant from 
Hoechst Marion Roussel, Inc. 
29 
References 
1. Aapro MS (1991) 5-HT3 receptor an- 
tagonists. An overview of their pres- 
ent status and future potential in can- 
cer therapy-induced mesis. Drugs 
42: 551-568 
2. Allen JC, Gralla R, Reilly L, et al 
(1985) Metoclopramide: dose-related 
toxicity and preliminary antiemetic 
studies in children receiving cancer 
chemotherapy. J Clin Oncol 3:1136- 
1141 
3. Audhuy B, Cappelaere P, Claverie N, 
et al (1995) Double-blind comparison 
of the antiemetic efficacy of two sin- 
gle iv doses of dolasetron and one iv 
dose of granisetron after cisplatin 
(_> 80 mg/m 2) chemotherapy (ab- 
stract). Support Care Cancer 5:338 
4. Bateman DN, Rawlins MD, Simpson 
JM (1985) Extrapyramidal reactions 
with metoclopramide. BMJ 291:930- 
932 
5. Bigaud M, Elands J, Kastner PR, et 
al (1995) Pharmacology of the human 
metabolites of dolasetron, an antie- 
metic 5-HT3 receptor antagonist. 
Drug Dev Res 34:289-296 
6. Boeijinga PH, Galvan M, Baron BM, 
et al (1992) Characterization f the 
novel 5-HT3 antagonists MDL 
73147EF (dolasetron mesylate) and 
MDL 74156 in NG108-15 neuroblas- 
toma x glioma cells. Eur J Pharmacol 
219: 9-13 
7. Boxenbaum H, Gillespie T, Heck K, 
et al (1992) Human dolasetron phar- 
macokinetics. I. Disposition following 
single-dose intravenous administra- 
tion to normal male subjects. Bio- 
pharm Drug Dispos 13:693-701 
8. Conroy T, Cappelaere P, Fabbro M, 
et al (1994) Acute antiemetic efficacy 
and safety of dolasetron mesylate, a 
5-HT3 antagonist, in cancer patients 
treated with cisplatin. Am J Clin On- 
col 17:97-102 
9. Cooper S, Georgiou V (1992) The 
impact of cytotoxic hemotherapy - 
perspectives from patients, pecialists 
and nurses. Eur J Cancer 28A 
[Suppl 1] : $36-$38 
10. Cunningham D, Soukop M, Gilchrist 
NL, et al (1985) Randomised trial of 
intravenous high-dose metoclopram- 
ide and intramuscular chlorpromazine 
in controling nausea nd vomiting in- 
duced by cytotoxic drugs. BMJ 
290: 604-605 
11. D'Aquisto R, Tyson LB, Gralla RJ, 
et al (1986) The influence of chronic 
high alcohol intake on chemotherapy- 
induced nausea nd vomiting (ab- 
stract). Proc Am Soc Clin Oncol 
5:257 
12. De Mulder PHM, Seynaeve C, Ver- 
morken JB, et al (1990) Ondansetron 
compared with high-dose metoclo- 
pramide in prophylaxis of acute and 
delayed cisplatin-induced nausea nd 
vomiting. Ann Intern Med 113:834- 
840 
13. Galvan M, Gittos MW, Fatmi M 
(1993) Dolasetron mesylate. Drugs 
Future 18: 506-509 
14. Gordon C J, Pazdur R, Ziccarelli A, 
et al (1989) Metoclopramide v rsus 
metoclopramide and lorazepam: su- 
periority of combined therapy in the 
control of cisplatin-induced emesis. 
Cancer 63 : 578-582 
15. Gralla RJ (1993) Current issues in 
the management of nausea nd vom- 
iting. Ann Oncol 4 [Suppl 3]:$3-$7 
16. Gralla RJ, Itri LM, Pisko SE, et al 
(1981) Antiemetic efficacy of high- 
dose metoclopramide: randomised 
trials with placebo and prochlorpera- 
zine in patients with chemotherapy 
induced nausea nd vomiting. N Engl 
J Med 305 :905-909 
17. Gralla RJ, Tyson LB, Kris MG, et al 
(1987) The management of chemo- 
therapy-induced nausea nd vomiting. 
Med Clin North Am 72:289-300 
18. Grunberg SM, Hesketh PJ (1993) 
Control of chemotherapy-induced 
emesis. N Engl J Med 329:1790-1796 
19. Grunberg SM, Stevenson LL, Russell 
CA, et al (1989) Dose ranging phase 
I study of the serotonin antagonist 
GR38032F for prevention of cisplatin- 
induced nausea nd vomiting. J Clin 
Oncol 7 : 1137-1141 
20. Hainsworth J, Harvey W, Pendergrass 
K, et al (1991) A single-blind com- 
parison of intravenous ondansetron, 
a selective serotonin antagonist, with 
intravenous metoclopramide in the 
prevention of nausea nd vomiting 
associated with high-dose cisplatin 
chemotherapy. J Clin Oncol 9:721- 
728 
21. Harman GS, Omura GA, Ryan K, 
Hainsworth JD, Cramer MB, Hahne 
WF (1996) A randomized, ouble- 
blind comparison of single-dose and 
divided multiple-dose dolasetron for 
cisplatin-induced emesis. Cancer Che- 
mother Pharmacol 38: 323-328 
22. Hesketh PJ (1991) Serotonin antag- 
onists: a new class of antiemetic 
agents. J Natl Cancer Inst 83:613-620 
23. Hesketh P J, Gandara DR, Hesketh 
AM, et al (1996) Dose-ranging evalu- 
ation of the antiemetic efficacy of in- 
travenous dolasetron i  patients re- 
ceiving chemotherapy with doxorubi- 
cin or cyclophosphamide. Support 
Care Cancer 4:141-146 
24. Kirchner V, Aapro M, Alberto P, et 
al (1993) Early clinical trial of MDL 
73,147 EF: a new 5HT3-receptor an- 
tagonist for the prevention of chemo- 
therapy-induced nausea nd vomiting. 
Ann Oncol 4:481-484 
25. Kris MG, Gralla RJ, Tyson LB, et al 
(1985) Improved control of cisplatin- 
induced emesis with high-dose meto- 
clopramide and with combinations of 
metoclopramide, xamethasone, and 
diphenhydramine. R sults of consecu- 
tive trials in 255 patients. Cancer 
55 : 527-534 
26. Kris MG, Gralla RJ, Clark R J, et al 
(1987) Antiemetic ontrol and pre- 
vention of side effects of anticancer 
therapy with lorazepam or diphenhy- 
dramine when used in combination 
with metoclopramide plus dexametha- 
sone. Cancer 60:2816-2822 
27. Kris MG, Grunberg SM, Gralla R J, 
et al (1994) Dose-ranging evaluation 
of the serotonin antagonist dolasetron 
mesylate in patients receiving high- 
dose cisplatin. J Clin Oncol 12:1045- 
1049 
28. Lazlo J (1983) Nausea and vomiting 
as major complications of cancer che- 
motherapy. Drugs 25 [8uppl 1]:1-7 
29. Markham A, Sorkin EM (1993) On- 
dansetron. An update of its thera- 
peutic use in chemotherapy-induced 
and postoperative nausea nd vomit- 
ing. Drugs 45 : 931-952 
30. Marty M, Pouillart P, Scholl S, et al 
(1990) Comparison of the 5-hydroxy- 
tryptamine-3 (serotonin) antagonist 
ondansetron (GR 38032F) with high- 
dose metoclopramide in the control 
of cisplatin-induced emesis. N Engl J 
Med 322: 816-821 
31. Merrouche Y, Catimel G, Rebattu P, 
et al (1994) A phase I antiemetic 
study of MDL 73,147EF, a novel 5- 
hydroxytryptamine antagonist in can- 
cer patients receiving emetogenic che- 
motherapy. Ann Oncol 5:549-551 
32. Miller RC, Galvan M, Gittos MW, et 
al (1993) Pharmacological properties 
of dolasetron, a potent and selective 
antagonist a 5-HT3 receptors. Drug 
Dev Res 28 : 87-93 
33. Navari RM, Kaplan HG, Gralla RJ, 
et al (1994) Efficacy and safety of 
granisetron, a selective 5-hydroxy- 
tryptamine-3 receptor antagonist, in
the prevention of nausea nd vomit- 
ing induced by high-dose cisplatin. 
J Clin Oncol 12:2204-2210 
34. Peace KM (1990) Statistical issues in 
drug research and development. Dek- 
ker, New York 
30 
35. Riviere A (1994) Dose finding study 
of granisetron i patients receiving 
high-dose cisplatin chemotherapy. Br 
J Cancer 69: 967-971 
36. Roila F, Tonato M, Basurto C, et al 
(1987) Anti-emetic activity of high- 
dose metoclopramide combined with 
methylprednisolone versus metoclo- 
pramide alone in cisplatin-treated 
cancer patients: a randomized double- 
blind trial of the Italian Oncology 
Group for Clinical Research. J Oncol 
5 : 141-149 
37. Sledge GW Jr, Einhorn L, Nagy C, et 
al (1992) Phase III double-blind com- 
parison of intravenous ondansetron 
and metoclopramide as antiemetic 
therapy for patients receiving multi- 
ple-day cisplatin-based chemotherapy. 
Cancer 70: 2524-2528 
38. Sullivan JR, Leyden MJ, Bell R 
(1983) Decreased cisplatin induced 
nausea nd vomiting with chronic al- 
cohol ingestion. N Engl J Med 
309 :796-797 
39. Tortorice PV, O'Connell MB (1990) 
Management of chemotherapy-in- 
duced nausea nd vomiting. Pharma- 
cotherapy 10:129-145 
40. Warrington PS, Allan SG, Cornbleet 
MA, et al (1986) Optimising anti- 
emetics in cancer chemotherapy: effi- 
cacy of continuous versus intermittent 
infusion of high-dose metoclopramide 
in emesis induced by cisplatin. BMJ 
293:1334-1337 
41. Yielding A, Bertoli L, Eisenberg P, et 
al (1996) Antiemetic efficacy of two 
different single intravenous doses of 
dolasetron i  patients receiving high- 
dose cisplatin-containing chemothera- 
py. Am J Clin Oncol (in press) 
